Bayer Aktiengesellschaft (ETR:BAYN)

Germany flag Germany · Delayed Price · Currency is EUR
27.76
+1.01 (3.78%)
Jun 11, 2025, 5:44 PM CET
1.00%
Market Cap 26.27B
Revenue (ttm) 46.58B
Net Income (ttm) -3.25B
Shares Out 982.42M
EPS (ttm) -3.32
PE Ratio n/a
Forward PE 6.75
Dividend 0.11 (0.41%)
Ex-Dividend Date Apr 28, 2025
Volume 5,947,502
Average Volume 3,513,166
Open 27.33
Previous Close 26.75
Day's Range 27.08 - 27.88
52-Week Range 18.38 - 31.03
Beta 0.98
RSI 78.38
Earnings Date May 13, 2025

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skin... [Read more]

Sector Healthcare
Founded 1863
Employees 90,587
Stock Exchange Deutsche Börse Xetra
Ticker Symbol BAYN
Full Company Profile

Financial Performance

In 2024, Bayer Aktiengesellschaft's revenue was 46.61 billion, a decrease of -2.16% compared to the previous year's 47.64 billion. Losses were -2.55 billion, -13.23% less than in 2023.

Financial Statements

News

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

BERLIN & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bayer and the Broad Institute today announced that they have extended their research collaboration of 10 years by an additional five years, to further advan...

12 hours ago - Business Wire

Bayer Crop Science delegation visits ISARC

Bayer Crop Science delegation visits ISARC : A four-member delegation from Bayer Crop Science visited the International Rice Research Institute - Sout.

7 days ago - The Times of India

Vividion Therapeutics and Bayer Further Strengthen Oncology Development Pipeline with Clinical-Stage WRN Inhibitor

SAN DIEGO & BERLIN, Germany--(BUSINESS WIRE)--Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, ...

7 days ago - Business Wire

Bayer to Share New Data from KERENDIA® (finerenone) Clinical Trial Program at European Renal Association Congress

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that it will present multiple new analyses of the KERENDIA ® (finerenone) clinical trial program at the European Renal Association (ERA) 62nd Con...

8 days ago - Business Wire

Bayer wins EU watchdog's endorsement for longer Eylea treatment intervals

German drugmaker Bayer on Friday won an endorsement by the European Medicines Agency to extend the intervals between shots of its anti-blindness treatment Eylea, giving it a potential edge over Roche'...

19 days ago - Reuters

Bayer Launches Centafore Imaging Core Lab to Support Imaging for Clinical Trials and Software as a Medical Device Development

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced the launch of its Imaging Core Lab Services under the brand name Centafore. With over 25 years of experience supporting more than 200 clinical tr...

20 days ago - Business Wire

Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

TEL AVIV, Israel , May 22, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for cardiometabolic diseases and GI ...

20 days ago - Benzinga

Bayer Highlights New Data from Oncology and Women's Health Portfolios at 2025 ASCO Annual Meeting

WHIPPANY, N.J.--(BUSINESS WIRE)--The latest data from studies across Bayer's oncology and women's health portfolios will be presented at the upcoming 2025 American Society of Clinical Oncology (ASCO) ...

21 days ago - Business Wire

Bayer CEO on managing through the good and bad: Call out the problems

Bayer CEO Bill Anderson takes the stage at the 2025 CNBC CEO Council Summit to talk to leaders about managing through uncertainty and tackling problems head-on.

21 days ago - CNBC

Dr. Yesmean Wahdan from Bayer Discusses Women's Health Month with YourUpdateTV

May is Women's Health Month – Dr. Yesmean Wahdan Shares Important and Timely Tips to Help Women Prioritize Their Health at Every Life Stage May is Women's Health Month – Dr. Yesmean Wahdan Shares Impo...

23 days ago - GlobeNewsWire

Fluor-Built Pharmaceutical Facility in California is First Industrial Manufacturing Facility in Western United States to Achieve LEED v4 Platinum Certification

Fluor Corporation (NYSE: FLR) announced today that Bayer’s Cell Therapy Launch Facility in Berkeley, California, has been designated the first industrial manufacturing facility in the Western United S...

23 days ago - Wallstreet:Online

Bayer seeks Roundup settlement, explores Monsanto bankruptcy, WSJ reports

Bayer is seeking to resolve lawsuits related to its Roundup weedkiller, while exploring a bankruptcy for its Monsanto unit if the settlement plan fails, the Wall Street Journal reported on Thursday, c...

26 days ago - Reuters

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy

The agricultural giant is preparing to place its U.S. subsidiary Monsanto in bankruptcy if a settlement with tort plaintiffs fails

26 days ago - WSJ

Bayer US head says FDA chief reassured pharma executives of timely reviews

Bayer Pharmaceuticals' chief operating officer said the head of the top U.S. drug regulator recently reassured industry executives that the Food and Drug Administration would meet its targets for revi...

26 days ago - Reuters

Bayer exec: Trump pharma tariffs would negatively impact R&D

Tariffs on pharma products could hinder R&D efforts, says Bayer exec. Read more here

27 days ago - Seeking Alpha

EQS-PVR: Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

EQS Voting Rights Announcement: Bayer Aktiengesellschaft Bayer Aktiengesellschaft: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Euro...

27 days ago - Wallstreet:Online
OSZAR »